## PODD: Insulet Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -8.3% below STRENGTH zone (4.0-10.0%); PEG 2.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($279.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 1)

**1. Insulet Corp. stock underperforms Friday when compared to competitors**
- Source: MarketWatch | 20251205T170500 | Bearish | Relevance: 100%
- Insulet Corp. (PODD) stock fell 3.62% to $304.49 on Friday, underperforming the broader market despite a positive trading session for the S&P 500 Index and Dow Jones Industrial Average. The stock closed 14.20% below its 52-week high of $354.88, which it reached on November 20th.

**2. FDA Clearance Of Lower-Target Omnipod 5 Upgrade Could Be A Game Changer For Insulet (PODD)**
- Source: Simply Wall Street | 20251205T155544 | Bullish | Relevance: 100%
- Insulet Corporation received FDA clearance for significant enhancements to its Omnipod 5 Automated Insulin Delivery System, introducing a 100 mg/dL target glucose option and improved automation. This upgrade offers greater personalization and consistent automated mode usage for patients, supporting the company's investment narrative amidst competitive pressures. The company aims for a broader rollout in the US in the first half of 2026, reinforcing its strategy to scale a single core platform globally.

**3. Insulet Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251205T070835 | Bullish | Relevance: 100%
- Insulet Corp. (PODD) shares rose 2.72% to $315.92 on Thursday, outperforming a mixed stock market. This gain broke a three-day losing streak for the company's stock. The S&P 500 Index saw a slight increase, while the Dow Jones Industrial Average experienced a minor decline.

**4. FDA OKs Algorithm Updates to Insulet’s Omnipod 5 Insulin Pump**
- Source: Medical Product Outsourcing | 20251204T151542 | Bullish | Relevance: 100%
- Insulet has received FDA 510(k) clearance for enhancements to its Omnipod 5 automated insulin delivery (AID) system. These updates to the Omnipod 5 algorithm include a lower 100 mg/dL Target Glucose option and a more seamless automated experience. The new features are expected to launch in the U.S. in the first half of 2026 for individuals aged 2 and older with type 1 diabetes and aged 18 and older with type 2 diabetes.

**5. Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience**
- Source: BioSpace | 20251204T150448 | Bullish | Relevance: 100%
- Insulet Corporation has received FDA 510(k) clearance for significant enhancements to its Omnipod 5 Automated Insulin Delivery System. These updates include a new 100 mg/dL Target Glucose setting for more customization and improved glucose management, alongside an enhanced algorithm to keep users in Automated Mode longer. The improvements are expected to launch in the U.S. in the first half of 2026 for individuals aged 2 and older with type 1 diabetes and aged 18 and older with type 2 diabetes.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 13, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Canaccord Genui | $432 | $428 | +1% |
| 2025-11-21 | Truist Securiti | $412 | $390 | +6% |
| 2025-11-21 | RBC Capital | $380 | $370 | +3% |
| 2025-11-21 | BTIG | $380 | $370 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Canaccord Genui | main | Buy |
| 2025-11-21 | Truist Securiti | main | Buy |
| 2025-11-21 | RBC Capital | main | Outperform |
| 2025-11-21 | BTIG | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($0.80M) |
| Sells | 1 ($0.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+1.0%)
- FMR, LLC: 10.8% (+0.8%)
- Blackrock Inc.: 9.4% (+2.8%)
- Capital Research Glo: 6.5% (-4.0%)
- State Street Corpora: 4.4% (+1.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Premium valuation (P/E 49x, PEG 2.2x) vulnerable to multiple compression.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 13 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.15 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (2.9x). Revenue growth strong at 21% YoY. Analyst sentiment positive (13 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.3B |
| Beta | 1.38 |
| 52W Range | $230.05 - $354.88 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.15 |
| Forward P/E | 49.2 |
| Current P/E | 62.3 |
| YoY Growth | 26.4% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -5.8% to -8.3% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 12.3pp (needs >4.0% for momentum thesis). AM_20 at -6.2% indicates price below own 20MA trend. Underperforming sector by 6.0pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.01x) but short-term weakness (below SMA20). MACD histogram bearish (-2.83), momentum weakening. RSI neutral at 41. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -8.32% (CS: 3) | Weak |
| RSI_14 | 41.0 | Neutral |
| MACD Histogram | -2.83 | Bearish |
| vs SMA20 | 0.939x | Below |
| vs SMA50 | 0.951x | Below |
| vs SMA200 | 1.013x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $304.49
- **Stop Loss:** $279.89 (8.1% risk)
- **Target:** $329.09 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $6,089.80
- **Portfolio %:** 6.09%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-19 (Est: $1.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.15 | $1.24 | +8.1% |
| 2025Q2 | $0.92 | $1.17 | +26.8% |
| 2025Q1 | $0.79 | $1.02 | +29.7% |
| 2024Q4 | $1.02 | $1.15 | +12.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*